SEROQUEL XR Drug Patent Profile

When do Seroquel Xr patents expire, and what generic alternatives are available?

Seroquel Xr is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-three drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Seroquel Xr

A generic version of SEROQUEL XR was approved as quetiapine fumarate by ACCORD HLTHCARE on March 27^th, 2012.

Summary for SEROQUEL XR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for SEROQUEL XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	150 mg	022047	1	2008-11-17
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	50 mg	022047	1	2008-10-17
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	400 mg	022047	1	2008-06-18
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	200 mg and 300 mg	022047	1	2008-06-12

US Patents and Regulatory Information for SEROQUEL XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-001	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-003	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-005	Aug 11, 2008	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-002	May 17, 2007	AB	RX	Yes	Yes
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-004	May 17, 2007	AB	RX	Yes	No

International Patents for SEROQUEL XR

See the table below for patents covering SEROQUEL XR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2019379
United Kingdom	8706949
Germany	3765969
South Korea	900001868
Australia	7045987
Mexico	9202951	NUEVA DIBENZOTIAZEPINA ANTIPSICOTICA.
European Patent Office	0240228	THIAZEPINE COMPOUNDS

Supplementary Protection Certificates for SEROQUEL XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0240228	9/2000	Austria		PRODUCT NAME: QUETIAPIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-23460, 1-23461 1-23463 20000113; FIRST REGISTRATION: GB 12619/0112 - 12619/0114 19970731
0240228	C980022	Netherlands		PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731
0240228	2000C/015	Belgium		PRODUCT NAME: QUETIAPINE FUMARAT (EQUIV. MET 25MG QUETIAPINE BASE); REGISTRATION NO/DATE: 624 S 309 F 3 20000207; FIRST REGISTRATION: GB PL 12619/0113 19970731
0240228	SPC/GB97/086	United Kingdom		PRODUCT NAME: QUETIAPINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: UK 12619/0112 19970731; UK 12619/0113 19970731; UK 12619/0114 19970731

Analysis of SEROQUEL XR: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

SEROQUEL XR (quetiapine fumarate extended release) is an antipsychotic medication developed by AstraZeneca, primarily indicated for schizophrenia, bipolar disorder, and adjunctive treatment of depression. Its patent expiry, competitive landscape, and market penetration influence its financial outlook. This report details the investment scenario, current market dynamics, and projected financial trajectory for SEROQUEL XR, emphasizing key growth drivers, risks, and competitive factors relevant to investors and stakeholders.

---

1. Market Overview and Portfolio Positioning

Parameter	Details
Therapeutic Area	Psychiatry: Schizophrenia, bipolar disorder, depression
Formulation	Extended-release (XR) multiparticulates
Initial Launch Date	2009 (United States), varies globally
Patents & Exclusivity	Patent protection expired in key markets by 2019; generics entered post-expiry

Market Size & Growth

• Global Antipsychotic Market (2022–2027): Estimated CAGR of 3.9%
• Market Value (2022): Approx. $13 billion, with SEROQUEL XR comprising a significant segment
• Region Breakdown:
  • North America: ~45%
  • Europe: ~25%
  • Asia-Pacific: Growing at 6-8% annually
  • Emerging markets expanding due to increasing prevalence and healthcare expenditure

Key Competitors

Brand	Active Ingredient	Formulations	Market Position	Patent Status
Abilify (aripiprazole)	Aripiprazole	XR, oral	Leading antipsychotic	Patent expired in 2015 (USP)
Risperdal (risperidone)	Risperidone	Oral, long-acting	Market share significant	Patent expired; generics available
Brexpiprazole (Rexulti)	Brexpiprazole	Oral	Emerging competitor	Patents pending or active

---

2. Investment Scenario

2.1 Historical Performance & Patent Impact

Timeline	Event	Impact
2009	SEROQUEL XR launched	Rapid uptake driven by extended-release profile
2019	Patent expiration in key markets	Entry of generics, pressure on revenues
2020–2022	Market saturation	Revenue plateau, decline in sales
2023	Emergence of biosimilars and new efficient competitors	Market risks increase

2.2 Revenue Trends and Projections

Year	Worldwide Sales (USD billion)	Comments
2018	1.3	Peak pre-patent expiry
2019	0.9	Post-patent decline begins
2020	0.7	Generics impact intensifies
2022	0.6	Market share stabilizing, decline slowing
2023–2027	Projected CAGR of approx. 2–3%	Driven by emerging markets, new formulations, and combination therapies

2.3 Investment Risks

Risk Factor	Details	Mitigation Strategies
Patent expiry	Accelerates generic competition	Diversify portfolio, develop biosimilars, expand indications
Market penetration	Slower adoption in emerging markets	Local partnerships, price optimization
Regulatory changes	Stricter approval pathways	Strategic clinical trials, adaptive regulatory strategies
Competitive innovation	New pharmacological agents	Investment in R&D, real-world evidence

---

3. Market Dynamics

3.1 Growth Drivers

• Increasing prevalence of schizophrenia (~1% globally) and bipolar disorder (~1.2%)
• Rising healthcare expenditure in emerging markets to improve access
• Advancements in pharmacology enabling more tolerable, targeted therapies
• Combination Treatment Approaches: Augmentation strategies with antidepressants or mood stabilizers
• Patient Compliance: XR formulations improve adherence

3.2 Market Challenges

• Generic Competition: Cost pressures reduce profit margins
• Drug Switching & Off-Label Use: Impacted by newer agents with better side-effect profiles
• Pricing & Reimbursement Policies: Varying across regions, affecting sales
• Regulatory Hurdles: Drug approvals for new indications face delays

---

4. Financial Trajectory: Short- and Long-term Outlook

Timeframe	Expected Revenue Trend	Key Factors
2023–2025	Slight decline or stabilization	Navigating generic competition, optimizing sales strategies
2026–2030	Potential stabilization or modest growth	Expansion into new indications, new formulations, better market access

Forecast Comparison Table

Scenario	Revenue Estimate (USD billion)	Growth Rate	Key Assumptions
Conservative	0.5–0.6	Flat to slight decline (0–2%)	Generics dominate, limited new indications
Moderate	0.6–0.8	2–4%	Effective generic management, market expansion
Aggressive	0.8–1.0	4–7%	New indications, formulations, market penetration

---

5. Competitive Landscape & Strategic Positioning

Factor	Details	Implications
Patent Litigation	Strategies to delay generic entry	Investing in legal defenses, patent extensions
Formulation Innovations	Long-acting injectables, combinatorial drugs	Diversification of product portfolio
Market Expansion	Focus on Asia-Pacific, Latin America	Local partnerships, tailored pricing
Clinical Evidence	Efficacy and safety data for new indications	R&D focus, regulatory submissions

---

6. Policy and Regulatory Environment

Region	Key Policies	Impact on SEROQUEL XR	Strategic Response
United States	Medicaid formulary guidelines, patent protection	Patent cliffs; market share erosion	Diversify indications, cost-effective positioning
EU	Reimbursement policies, EMA approvals	Similar patent expiry effects	Market access strategies, biosimilar considerations
Asia-Pacific	Evolving drug approval pathways	Opportunities for growth	Local clinical trials, pricing negotiations

---

7. Comparative Analysis: SEROQUEL XR vs. Competitors

Parameter	SEROQUEL XR	Abilify Maintena	Risperdal Consta	Brexpiprazole
Indications	Schizophrenia, bipolar, adjunctive depression	Schizophrenia, maintenance	Schizophrenia, bipolar	Schizophrenia, major depressive disorder
Formulations	XR, oral	Long-acting injectable	Long-acting injectable	Oral, investigational
Patent Expiry / Biosimilar Entry	2019 (key markets)	2015	2019	Pending
Market Share (2022)	~20–25% (globally)	Similar	Similar	Emerging

---

8. FAQs

1. What is the current patent status of SEROQUEL XR, and how does it impact market competition?

SEROQUEL XR's primary patents expired in 2019 across many markets, leading to the entry of generics. This transition has significantly reduced revenue and market share, prompting AstraZeneca to explore new indications and formulations to sustain its market presence.

2. Which markets offer the most growth opportunity for SEROQUEL XR?

Emerging markets in Asia-Pacific and Latin America present significant growth potential due to increasing healthcare investment, rising prevalence of mental health disorders, and expanding insurance coverage. Additionally, expanding approved indications and improved access can open new revenue streams.

3. How does SEROQUEL XR compare with newer antipsychotic agents?

While SEROQUEL XR maintains a strong market presence due to its established efficacy and formulation, newer agents like brexpiprazole or cariprazine may offer better side effect profiles or novel mechanisms, challenging SEROQUEL XR’s market share.

4. What strategic initiatives are likely to ensure SEROQUEL XR's financial sustainability?

Key initiatives include developing additional indications, leveraging formulation innovations (e.g., long-acting injectables), patenting new combinations, and expanding into underserved markets through strategic partnerships and pricing strategies.

5. What are the key factors influencing SEROQUEL XR’s future profitability?

Major drivers include patent management, market expansion, differentiation through formulations, adverse event profiles, competitive landscape, regulatory approval processes, and reimbursement policies.

---

9. Key Takeaways

• Market Dynamics: Post-patent expiry, SEROQUEL XR faces increased generic competition, with a declining but stable market presence expected through 2025.
• Growth Opportunities: Expansion into emerging markets, new indications, and innovative formulations (long-acting injectables) are critical for future revenue.
• Investment Risks: Patent cliffs, market saturation, and competitive innovations challenge sustained profitability.
• Strategic Responses: Diversification, patent strategies, clinical trial development, and market access initiatives are essential.
• Financial Outlook: Moderate growth prospects from 2026 onward depend on successful product pipeline expansion and market penetration strategies.

---

References

1. GlobalData Healthcare. (2022). Global Antipsychotics Market Analysis.
2. AstraZeneca Annual Reports (2018–2022). Financial and operational performance.
3. IQVIA. (2023). Pharmaceutical Market Reports.
4. European Medicines Agency (EMA). (2022). Regulatory Status of Antipsychotics.
5. EvaluatePharma. (2023). Product Forecast Data.

---

This comprehensive analysis aims to inform strategic investment considerations and facilitate data-driven decisions regarding SEROQUEL XR’s market potential and financial trajectory.